A relational agent for treating substance use in adults: A randomized controlled trial with a psychoeducational comparator.

J Subst Use Addict TreatApr 24, 2026 (epub)
Clinical ResearchPsychiatry

Judith J Prochaska, Maggie Wang, Amy Chieng et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy of the Woebot for Substance Use Disorders (W-SUD) app in reducing substance use occasions among U.S. adults with problematic substance use. The study involved 258 participants and found no significant treatment effect between W-SUD and a psychoeducational control, with both groups showing moderate to large reductions in substance use at the end of treatment and at one-month follow-up.

Key findings

  • Both W-SUD and psychoeducation groups showed a within-group change of -13.6 and -12.9 past-month substance use occasions, respectively.
  • No significant treatment effect was observed between W-SUD and psychoeducation (beta = -0.675, p = 0.741).
  • Decreases in substance use occasions correlated with reductions in anxiety and depression across both groups.
  • Participants sent a median of 322.5 in-app messages during the W-SUD intervention.

Why it matters

Digital mental health interventions like W-SUD may provide accessible support for individuals with substance use issues. Understanding their efficacy compared to traditional methods is crucial for integrating technology into treatment strategies.

Source

Published in J Subst Use Addict Treat. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.